Pfizer buys cancer drug firm Medivation for $14 bn
American pharmaceutical company Pfizer on Monday announced to buy US-based cancer drug maker Medivation in an all-cash deal worth $14 billion. Medivation is known for selling a leading prostate-cancer drug named 'Xtandi'. Besides Pfizer, pharmaceutical companies Sanofi, Merck & Co, Celgene Corp and Gilead Sciences were also interested in buying Medivation.